MEIHUA INTERNATIONAL MEDICAL TECHNOLOGIES cO., LTD. revenue by segment MHUAF

Annual Quarterly

MEIHUA INTERNATIONAL MEDICAL TECHNOLOGIES cO., LTD. splits its revenue into 8 lines in its filings. The largest line in fiscal 2025, which ended Dec 31, 2025 was Resales Of Sourced Disposable Medical Devices From Third Party Manufacturers at $32.9 million, 53% of the total.

USD in millions. The percent under a figure is the change from the year before.

Line	FY 2025 Dec 31, 2025	FY 2024 Dec 31, 2024	FY 2023 Dec 31, 2023	FY 2022 Dec 31, 2022	FY 2021 Dec 31, 2021
Revenue	62	97	97	103	104
Class II	—	—	73 -1.0% share 74.9%	73 -6.0% share 71.0%	78 share 75.1%
Purchased	—	49 +0.8% share 50.9%	49 share 50.4%	—	—
Resales Of Sourced Disposable Medical Devices From Third Party Manufacturers	33 -33.3% share 53.2%	49 +0.8% share 50.9%	49 -7.4% share 50.4%	53 -5.6% share 51.1%	56 share 53.8%
Self Manufactured Products	27 -42.7% share 44.1%	48 -1.2% share 49.1%	48 -4.6% share 49.6%	51 +5.1% share 48.9%	48 share 46.2%
Class I	—	—	—	16 +18.9% share 15.5%	13 share 13.0%
Other	—	—	7 -35.7% share 7.2%	11 +19.7% share 10.5%	9 share 8.7%
Class III	—	—	2 -19.2% share 2.5%	3 -9.8% share 3.0%	3 share 3.3%
Saa S Service And Development	2 share 2.6%	—	—	—	—

How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. More on our methodology.

Company profile

Industry: Surgical & Medical Instruments & Apparatus (SIC 3841)
Listed as: MHUAF (OTC)
Fiscal year ends: December 31
Incorporated in: Cayman Islands
Headquarters: Yangzhou, China
SEC filer status: Non-accelerated filer, Emerging growth company
SEC CIK: 1835615

Other Surgical & Medical Instruments & Apparatus companies

All 151 Surgical & Medical Instruments & Apparatus companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.